Syndax Pharmaceuticals, Inc. (SNDX) (“Syndax” or the “Company”) is a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company’s two lead product candidates are SNDX-5613, or revumenib, and SNDX-6352, or axatilimab. Revumenib is being developed for the treatment of MLL-rearranged acute leukemias and nucleophosmin 1 mutant acute myeloid leukemia. Axatilimab is a monoclonal antibody that that targets the colony stimulating factor 1 receptor in chronic graft-versus-host disease as well as idiopathic pulmonary fibrosis.